Overview

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

Status:
Completed
Trial end date:
2012-03-23
Target enrollment:
Participant gender:
Summary
This is a 2-part study in participants with renal impairment and matched healthy participants to investigate the effect of impaired renal function on the plasma and urine levels of omarigliptin (MK-3102) after taking a single 3 mg dose by mouth.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.